3 Stocks In Focus

Orthovita Inc. ( NASDAQ: VITA ) shares are soaring in today's trading. The small cap stock reached a high of $2.82 in early trading, and at last check, it was up 15.90% to $2.55, with volume up from daily average of 243,653 to 2.14 million. Orthovita shares have a 52-week range of $1.60-$4.68. Orthovita shares are soaring after the company received a clearance from the FDA to market Vitoss Bioactive Foam-2X Bone Graft Substitute in the U.S. Vitoss is used as non-structural bone void filler in the spine, pelvis and extremities. Orthovita is a Malvern, Pennsylvania-based specialty spine and orthopedic company. Pacer International Inc. ( NASDAQ: PACR ) announced its fourth-quarter full year financial results. The company reported fourth-quarter revenue of $373.3 million. The company's fourth-quarter net income fell by $10.4 million. It reported a loss per share of $0.03 in the fourth quarter of 2010. For full year 2010 the company reported an increase of $224 million in its operating income. Pacer International shares have a 52-week range of $2.74-$9.45. The stock is currently trading below its 50-day and 200-day moving averages. Pacer International shares gained 84.15% in the last one year. Pacer International is a Concord, California-based asset-light North American transportation and logistics services provider. Neurocrine Biosciences Inc. ( NASDAQ: NBIX ) shares are soaring in today's trading. The small cap stock reached a high of $8.40 in early trading, and at last check, it was up 9.60% to $8.05, with volume up from daily average of 345,434 to 631,710. Neurocrine Biosciences shares have a 52-week range of $2.13-$9.30. Neurocrine Biosciences shares are soaring after the company announced its fourth-quarter financial results. The company reported fourth-quarter profit of $2.5 million, or $0.04 per share, compared with a loss of $7.9 million, or $0.20 per share reported in the same period in the previous year. The company reported fourth-quarter revenue of $13.7 million, up from $740,000 reported for the same period in 2009. Neurocrine Biosciences is a San Diego, California-based company, engaged in the development, discovery, and commercialization of drugs for treatment of neurological and endocrine-related diseases and disorders. This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in these stocks. We reserve the right to buy or sell any stock mentioned in this report at any time after this post.
Negocioenlinea
tdp2664Penny Stock Live